Jeff Cislini - 28 Sep 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
General Counsel
Signature
/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini
Issuer symbol
RVMD
Transactions as of
28 Sep 2023
Net transactions value
-$56,394
Form type
4
Filing time
02 Oct 2023, 16:12:59 UTC
Previous filing
20 Sep 2023
Next filing
20 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Sale $50,524 -1,798 -4.3% $28.10 40,215 28 Sep 2023 Direct F1, F2, F3
transaction RVMD Common Stock Sale $5,870 -202 -0.5% $29.06 40,013 28 Sep 2023 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023.
F2 This transaction was executed in multiple trades in prices ranging from $27.84 to $28.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Includes 34,860 restricted stock units.
F4 This transaction was executed in multiple trades in prices ranging from $29.05 to $29.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.